Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase III Trial of Xcytrin (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer Undergoing Whole Brain Radiation Therapy

Trial Profile

Randomized Phase III Trial of Xcytrin (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer Undergoing Whole Brain Radiation Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Motexafin gadolinium (Primary)
  • Indications Cancer metastases; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SMART
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 15 Mar 2009 Primary endpoint results published in International Journal of Radiation Oncology Biology Physics 73: 1069-1076, No. 4, 15 Mar 2009
    • 21 Jul 2006 Status change
    • 29 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top